TScan Therapeutics, Inc.

TCRX Nasdaq SEC CIK 1783328
Follow TScan Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $586K −76.7% vs same quarter last year
Net income −$33.1M +7.4% vs same quarter last year
EPS, diluted −$0.25 +10.7% vs same quarter last year
Operating cash flow −$27.1M +16.6% vs same quarter last year
Revenue by quarter
$665K
$2.2M
$3.1M
$2.5M
$2.6M
$982K
$1.1M
$586K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$10.3M−$129.8M
FY24$2.8M−$127.5M
FY23$21M−$89.2M
FY22$13.5M−$66.2M
FY21$10.1M−$48.6M
FY20$1.1M−$26.1M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1315.4%−1256.8%
FY24−4787.7%−4527.7%
FY23−444%−423.9%
FY22−492.3%−489.3%
FY21−479.6%−479.5%
FY20−2417.8%−2408%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$139.7M
FY24−$114.6M
FY23−$64.5M
FY22−$70.7M
FY21−$58.6M
FY20−$7.3M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TScan Therapeutics
  • Healthcare median
−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTScan TherapeuticsHealthcare median
FY25−1256.8%−30.6%
FY24−4527.7%−47%
FY23−423.9%−58%
FY22−489.3%−80.4%
FY21−479.5%−71.8%
FY20−2408%−62.2%
FY19-−46.2%